Current Infectious Disease Reports

, Volume 8, Issue 6, pp 427–433

The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia



The last three decades have seen an expanding pool of high-risk patients susceptible to the opportunistic pathogen Candida. Accordingly, a dramatic increase in nosocomial blood stream infections (BSIs) due to Candida spp has been reported throughout the world, starting in tertiary care centers and spreading to community hospitals. This absolute increase in Candida BSIs was accompanied by both an absolute and then a proportional increase in invasive infection caused by reduced fluconazole-susceptible non-albicans Candida spp. Currently, the incidence trend of BSI has stabilized, and Candida albicans remains the most common species causing fungal BSI. Clinicians must be aware of the importance and implications of non-albicans Candida spp when selecting antifungal drugs, although most studies have not shown significant outcome differences with use of the various antifungal classes.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pappas PG, Rex JH, Lee J, et al.: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634–643.PubMedCrossRefGoogle Scholar
  2. 2.
    Morgan J: Global trends in candidemia: review of reports from 1995–2005. Curr Infect Dis Rep 2005, 7:429–439. Comprehensive review of epidemiology of BSI due to Candida spp worldwide.PubMedGoogle Scholar
  3. 3.
    Hajjeh RA, Sofair AN, Harrison LH, et al.: Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42:1519–1527.PubMedCrossRefGoogle Scholar
  4. 4.
    Eggimann P, Garbino J, Pittet D: Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3:685–702.PubMedCrossRefGoogle Scholar
  5. 5.
    Jarvis WR: Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995, 20:1526–1530.PubMedGoogle Scholar
  6. 6.
    Wisplinghoff H, Bischoff T, Tallent SM, et al.: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309–317.PubMedCrossRefGoogle Scholar
  7. 7.
    Martin GS, Mannino DM, Eaton S, Moss M:The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546–1554.PubMedCrossRefGoogle Scholar
  8. 8.
    Gudlaugsson O, Gillespie S, Lee K, et al.: Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172–1177.PubMedCrossRefGoogle Scholar
  9. 9.
    Mora-Duarte J, Betts R, Rotstein C, et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020–2029.PubMedCrossRefGoogle Scholar
  10. 10.
    Trick WE, Fridkin SK, Edwards JR, et al.: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 2002, 35:627–630.PubMedCrossRefGoogle Scholar
  11. 11.
    Roilides E, Farmaki E, Evdoridou J, et al.: Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis 2004, 23:745–750.PubMedCrossRefGoogle Scholar
  12. 12.
    Marr KA, Seidel K, White TC, Bowden RA: Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000, 181:309–316.PubMedCrossRefGoogle Scholar
  13. 13.
    Pfaller MA, Messer SA, Hollis RJ, et al.: In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998, 42:3242–3244.PubMedGoogle Scholar
  14. 14.
    Edwards JE Jr: Invasive candida infections-evolution of a fungal pathogen. N Engl J Med 1991, 324:1060–1062.PubMedCrossRefGoogle Scholar
  15. 15.
    Bedini A, Venturelli C, Mussini C, et al.: Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 2006, 12:75–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Malani A, Hmoud J, Chiu L, et al.: Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005, 41:975–981.PubMedCrossRefGoogle Scholar
  17. 17.
    San Miguel LG, Cobo J, Otheo E, et al.: Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 2005, 26:548–552.PubMedCrossRefGoogle Scholar
  18. 18.
    Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20:115–125.PubMedGoogle Scholar
  19. 19.
    Abi-Said D, Anaissie E, Uzun O, et al.: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122–1128.PubMedGoogle Scholar
  20. 20.
    Pfaller MA, Diekema DJ: Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004, 10(Suppl 1):11–23. Study of an enormous collection of Candida isolates observed worldwide and collected over 10 years, dealing with epidemiology and antifungal susceptibility.PubMedCrossRefGoogle Scholar
  21. 21.
    Pfaller MA, Messer SA, Boyken L, et al.: Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004, 42:3142–3146.PubMedCrossRefGoogle Scholar
  22. 22.
    Colombo AL, Melo AS, Crespo Rosas RF, et al.: Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis 2003, 46:253–257.PubMedCrossRefGoogle Scholar
  23. 23.
    Pfaller MA, Jones RN, Messer SA, et al.: National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998, 30:121–129.PubMedCrossRefGoogle Scholar
  24. 24.
    Shin JH, Kee SJ, Shin MG, et al.: Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002, 40:1244–1248.PubMedCrossRefGoogle Scholar
  25. 25.
    Clark TA, Slavinski SA, Morgan J, et al.: Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004, 42:4468–4472.PubMedCrossRefGoogle Scholar
  26. 26.
    Weinberger M, Leibovici L, Perez S, et al.: Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 2005, 61:146–154.PubMedCrossRefGoogle Scholar
  27. 27.
    White MH: The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 1997, 24:1129–1130.PubMedGoogle Scholar
  28. 28.
    Vazquez JA, Sobel JD, Peng G, et al.: Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin Infect Dis 1999, 28:1025–1031.PubMedGoogle Scholar
  29. 29.
    Lin MY, Carmeli Y, Zumsteg J, et al.: Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005, 49:4555–4560.PubMedCrossRefGoogle Scholar
  30. 30.
    Pfaller MA, Diekema DJ: Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004, 42:4419–4431.PubMedCrossRefGoogle Scholar
  31. 31.
    Pfaller MA, Jones RN, Doern GV, et al.: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998, 36:1886–1889.PubMedGoogle Scholar
  32. 32.
    Pfaller MA, Messer SA, Boyken L, et al.: Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 2003, 41:5729–5731.PubMedCrossRefGoogle Scholar
  33. 33.
    Ostrosky-Zeichner L, Rex JH, Pappas PG, et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47:3149–3154. Comparative in vitro activity of antifungals against large collection of Candida isolates.PubMedCrossRefGoogle Scholar
  34. 34.
    Diekema DJ, Pfaller MA, Jones RN, et al.: Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. Int J Antimicrob Agents 2000, 13:257–271.PubMedCrossRefGoogle Scholar
  35. 35.
    Borst A, Raimer MT, Warnock DW, et al.: Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother 2005, 49:783–787.PubMedCrossRefGoogle Scholar
  36. 36.
    Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD:Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006, 42:938–944.PubMedCrossRefGoogle Scholar
  37. 37.
    Zaoutis TE, Argon J, Chu J, et al.: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41:1232–1239.PubMedCrossRefGoogle Scholar
  38. 38.
    Imhof A, Balajee SA, Fredricks DN, et al.: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743–746.PubMedCrossRefGoogle Scholar
  39. 39.
    Pappas PG, Rex JH, Sobel JD, et al.: Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161–189. Infectious Diseases Society of America practice guidelines for prevention and therapy of all forms of candidiasis.PubMedCrossRefGoogle Scholar
  40. 40.
    Bodey GP, Mardani M, Hanna HA, et al.: The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002, 112:380–385.PubMedCrossRefGoogle Scholar
  41. 41.
    Reboli A, Rotstein C, Pappas P, et al.: Anidulafungins versus fluconazole for treatment of candidemia and invasive candidiasis. Paper presented at 45th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC; December 16–19, 2005. Landmark prospective randomized controlled study showing superiority of anidulafungin over fluconazole.Google Scholar
  42. 42.
    Panackal AA, Gribskov JL, Staab JF, et al.: Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006, 44:1740–1743.PubMedCrossRefGoogle Scholar
  43. 43.
    Barchiesi F, Spreghini E, Maracci M, et al.: In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob Agents Chemother 2004, 48:3317–3322.PubMedCrossRefGoogle Scholar
  44. 44.
    Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT: Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005, 49:4895–4902.PubMedCrossRefGoogle Scholar
  45. 45.
    Nguyen MH, Peacock JE Jr, Morris AJ, et al.: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 100:617–623.PubMedCrossRefGoogle Scholar
  46. 46.
    Magill SS, Shields C, Sears CL, et al.: Triazole crossresistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006, 44:529–535.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Division of Infectious DiseasesHarper University HospitalDetroitUSA

Personalised recommendations